Finance

Lists
Q3 2026 earnings • released • EPS beat +7.92% • Revenue beat +1.34%
See results
A1ZN34:BVMF
Astrazeneca Plc Bdr
R$168.92
0.00%
(0.00) 1D
Oct 30, 4:56:00 PM GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for A1ZN34...
Open
R$166.50
High
R$170.34
Low
R$166.50
Mkt. cap
289.79B
Avg. vol.
1.06K
Volume
2.87K
52-wk high
R$190.40
52-wk low
R$129.06
Shares outstanding
1.55B
No. of employees
96K
Open
R$166.50
High
R$170.34
Low
R$166.50
Mkt. cap
289.79B
Avg. vol.
1.06K
Volume
2.87K
52-wk high
R$190.40
52-wk low
R$129.06
Shares outstanding
1.55B
No. of employees
96K
News stories
From web sources and news partners
Profile
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden; and Gaithersburg, Maryland, US. AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia
About Astrazeneca Plc Bdr
CEOPascal Soriot
Employees96.1K
FoundedApr 6, 1999
HeadquartersCambridge, Cambridgeshire, United Kingdom
SectorPharmaceutical industry
Websiteastrazeneca.com
Last report
Oct 30, 2026
Fiscal period
Q3 2026
$2.79 / $2.59
+7.92%beat
Revenue / Est. (USD)
16.21B / 16.00B
+1.34%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
15.19B
15.50B
15.29B
15.38B
Cost of goods sold
2.79B
3.17B
2.67B
2.53B
Cost of revenue
2.79B
3.17B
2.67B
2.53B
Research and development expenses
3.63B
3.62B
3.47B
3.67B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.20B
5.32B
5.03B
5.72B
Operating expense
8.74B
8.99B
8.34B
9.24B
Total operating expenses
11.53B
12.16B
11.02B
11.78B
Operating income
3.66B
3.35B
4.27B
3.61B
Other non operating income
-
-247.00M
-
-
EBT including unusual items
3.24B
2.63B
3.91B
2.80B
EBT excluding unusual items
3.32B
3.05B
3.94B
3.24B
Income tax expense
709.00M
300.00M
833.00M
291.00M
Effective tax rate
21.86%
11.41%
21.28%
10.40%
Other operating expenses
-89.00M
53.00M
-155.00M
-152.00M
Net income
2.53B
2.33B
3.08B
2.51B
Net profit margin
16.67%
15.00%
20.15%
16.30%
Earnings per share
2.38
2.12
1.29
2.63
Interest and investment income
85.00M
135.00M
73.00M
80.00M
Interest expense
-434.00M
-155.00M
-393.00M
-435.00M
Net interest expenses
-349.00M
-20.00M
-320.00M
-355.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
5.21B
4.11B
5.64B
5.19B
Gain or loss from assets sale
-31.00M
-37.00M
-34.00M
-94.00M
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps